Aditxt, Inc. Deferred Compensation Arrangement with Individual, Compensation Expense
Aditxt, Inc. (ADTX) reported Deferred Compensation Arrangement with Individual, Compensation Expense of $0 for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-14.
Discontinued › Expense Statement › Operating Expenses
us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense · last filed 2024-04-16
- Aditxt, Inc. deferred compensation arrangement with individual, compensation expense for the quarter ending 2023-09-30 was $0.00, a 100.00% decline year-over-year.
- Aditxt, Inc. deferred compensation arrangement with individual, compensation expense for the quarter ending 2023-06-30 was $0.00, a 100.00% decline year-over-year.
- Aditxt, Inc. deferred compensation arrangement with individual, compensation expense for the quarter ending 2023-03-31 was $0.00, a 100.00% decline year-over-year.
- Aditxt, Inc. deferred compensation arrangement with individual, compensation expense for the quarter ending 2022-12-31 was -$513.58K.
- Aditxt, Inc. deferred compensation arrangement with individual, compensation expense for fiscal 2022 was $146.61K.
| Period end | Deferred Compensation Arrangement with Individual, Compensation Expense 3 month | Deferred Compensation Arrangement with Individual, Compensation Expense 6 month | Deferred Compensation Arrangement with Individual, Compensation Expense 9 month | Deferred Compensation Arrangement with Individual, Compensation Expense 12 month |
|---|---|---|---|---|
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $0.00 derived: sum of 2 quarters · filed 2023-11-14 | $0.00 10-Q · filed 2023-11-14 | -$513.58K derived: sum of 4 quarters · filed 2024-04-16 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $0.00 10-Q · filed 2023-08-14 | -$513.58K derived: sum of 3 quarters · filed 2024-04-16 | -$410.61K derived: sum of 4 quarters · filed 2024-04-16 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-15 | -$513.58K derived: sum of 2 quarters · filed 2024-04-16 | -$410.61K derived: sum of 3 quarters · filed 2024-04-16 | $120.35K derived: sum of 4 quarters · filed 2024-04-16 |
| 2022-12-31 | -$513.58K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-16 | -$410.61K derived: sum of 2 quarters · filed 2024-04-16 | $120.35K derived: sum of 3 quarters · filed 2024-04-16 | $146.61K 10-K · filed 2024-04-16 |
| 2022-09-30 | $102.97K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $633.93K derived: sum of 2 quarters · filed 2023-11-14 | $660.19K 10-Q · filed 2023-11-14 | |
| 2022-06-30 | $530.96K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $557.22K 10-Q · filed 2023-08-14 | ||
| 2022-03-31 | $26.26K 10-Q · filed 2023-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |